The Scientist

» industry and immunology

Most Recent

image: Follow the Funding

Follow the Funding

By | May 1, 2015

In times of budget belt-tightening at the federal level, life-science researchers can keep their work supported through private sources.  

9 Comments

image: Llamas as Lab Rats

Llamas as Lab Rats

By | May 1, 2015

From diagnostics to vaccines, llama antibodies point to new directions in HIV research.

0 Comments

image: Looking for Latent HIV

Looking for Latent HIV

By | May 1, 2015

Sequencing HIV integration sites suggests that clonally expanded T-cell populations may not be the main source of latent virus.

0 Comments

image: Soluble Signal

Soluble Signal

By | May 1, 2015

An immune protein previously thought to mark inactive T cells has a free-floating form that correlates with HIV disease progression.

0 Comments

image: Think Before You Fire

Think Before You Fire

By | May 1, 2015

Industry layoffs may save a few dollars, at the cost of losing the collective brainpower of thousands of scientists.

4 Comments

image: Defeating the Virus

Defeating the Virus

By | May 1, 2015

Recent discoveries are spurring a renaissance in HIV vaccine research and development.

0 Comments

image: Drugmaker Teva Bids $40 Billion for Mylan

Drugmaker Teva Bids $40 Billion for Mylan

By | April 23, 2015

The Israel-based pharmaceutical company makes an unsolicited offer for a smaller, Netherlands-based rival as its main product faces competition from generics.

0 Comments

image: Protein Spurs T-Cell Proliferation

Protein Spurs T-Cell Proliferation

By | April 17, 2015

A newly discovered protein promotes immunity to viruses and cancer by triggering the production of cytotoxic T cells.

1 Comment

image: Studying Ebola Survivors

Studying Ebola Survivors

By | April 6, 2015

A scientist jumps at the chance to study the blood of four Ebola survivors to better understand how the immune system responds to the deadly virus. 

1 Comment

image: Another CAR-T IPO

Another CAR-T IPO

By | April 6, 2015

Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.

0 Comments

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Human Cord Plasma Protein Boosts Cognitive Function in Older Mice
AAAS